Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Ionis Pharmaceuticals stock

Learn how to easily invest in Ionis Pharmaceuticals stock.

Ionis Pharmaceuticals Inc is a biotechnology business based in the US. Ionis Pharmaceuticals shares (IONS) are listed on the NASDAQ and all prices are listed in US Dollars. Ionis Pharmaceuticals employs 660 staff and has a trailing 12-month revenue of around $848.8 million.

How to buy shares in Ionis Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IONS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Ionis Pharmaceuticals stock price (NASDAQ: IONS)

Use our graph to track the performance of IONS stocks over time.

Ionis Pharmaceuticals shares at a glance

Information last updated 2022-09-18.
Latest market close$43.23
52-week range$25.04 - $48.82
50-day moving average $42.07
200-day moving average $36.43
Wall St. target price$50.17
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.03

Buy Ionis Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$100
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Tradier
Stocks, Options, ETFs
$0
$0
N/A
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Ionis Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ionis Pharmaceuticals price performance over time

Historical closes compared with the close of $43.23 from 2022-09-23

1 week (2022-09-15) -8.97%
1 month (2022-08-22) -1.79%
3 months (2022-06-23) 10.79%
6 months (2022-03-22) 19.16%
1 year (2021-09-24) 19.42%
2 years (2020-09-25) -11.23%
3 years (2019-09-26) 59.32
5 years (2017-09-26) 52.4

Is Ionis Pharmaceuticals stock undervalued or overvalued?

Valuing Ionis Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ionis Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Ionis Pharmaceuticals's PEG ratio

Ionis Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 25.7033. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ionis Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Ionis Pharmaceuticals's EBITDA

Ionis Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $14 million.

The EBITDA is a measure of a Ionis Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Ionis Pharmaceuticals financials

Revenue TTM $848.8 million
Gross profit TTM $164.6 million
Return on assets TTM -0.09%
Return on equity TTM -4.66%
Profit margin -3.32%
Book value $4.41
Market capitalisation $6.6 billion

TTM: trailing 12 months

Ionis Pharmaceuticals's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Ionis Pharmaceuticals.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Ionis Pharmaceuticals's total ESG risk score

Total ESG risk: 36.64

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Ionis Pharmaceuticals's overall score of 36.64 (as at 12/31/2018) is pretty weak – landing it in it in the 62nd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Ionis Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Ionis Pharmaceuticals's environmental score

Environmental score: 5.18/100

Ionis Pharmaceuticals's environmental score of 5.18 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Ionis Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Ionis Pharmaceuticals's social score

Social score: 26.17/100

Ionis Pharmaceuticals's social score of 26.17 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Ionis Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Ionis Pharmaceuticals's governance score

Governance score: 13.29/100

Ionis Pharmaceuticals's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Ionis Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Environmental, social, and governance (ESG) summary

Ionis Pharmaceuticals Inc was last rated for ESG on: 2019-01-01.

Total ESG score 36.64
Total ESG percentile 62.18
Environmental score 5.18
Environmental score percentile 9
Social score 26.17
Social score percentile 9
Governance score 13.29
Governance score percentile 9

Ionis Pharmaceuticals share dividends

We're not expecting Ionis Pharmaceuticals to pay a dividend over the next 12 months.

Ionis Pharmaceuticals share price volatility

Over the last 12 months, Ionis Pharmaceuticals's shares have ranged in value from as little as $25.04 up to $48.82. A popular way to gauge a stock's volatility is its "beta".

IONS.US volatility(beta: 0.64)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ionis Pharmaceuticals's is 0.6388. This would suggest that Ionis Pharmaceuticals's shares are less volatile than average (for this exchange).

Ionis Pharmaceuticals overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc. ; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc.

Frequently asked questions

What percentage of Ionis Pharmaceuticals is owned by insiders or institutions?
Currently 0.591% of Ionis Pharmaceuticals shares are held by insiders and 87.954% by institutions.
How many people work for Ionis Pharmaceuticals?
Latest data suggests 660 work at Ionis Pharmaceuticals.
When does the fiscal year end for Ionis Pharmaceuticals?
Ionis Pharmaceuticals's fiscal year ends in December.
Where is Ionis Pharmaceuticals based?
Ionis Pharmaceuticals's address is: 2855 Gazelle Court, Carlsbad, CA, United States, 92010
What is Ionis Pharmaceuticals's ISIN number?
Ionis Pharmaceuticals's international securities identification number is: US4622221004
What is Ionis Pharmaceuticals's CUSIP number?
Ionis Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 462222100

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site